- PA5-55926 - Invitrogen Antibodies KDF1 antibody

Submitted references KDF1, a Novel Tumor Suppressor in Clear Cell Renal Cell Carcinoma.

Zheng JM, Gan MF, Yu HY, Ye LX, Yu QX, Xia YH, Zhou HX, Bao JQ, Guo YQ
Frontiers in oncology 2021;11:686678

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescent staining of KDF1 in human cell line A-431 shows positivity in plasma membrane, the Golgi apparatus & nucleus but excluded from the nucleoli. Samples were probed using a KDF1 Polyclonal Antibody (Product # PA5-55926).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemical analysis of KDF1 in human Skin using KDF1 Polyclonal Antibody (Product # PA5-55926) shows moderate cytoplasmic positivity in squamous epithelial cells.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemical analysis of KDF1 in human Stomach using KDF1 Polyclonal Antibody (Product # PA5-55926) shows strong cytoplasmic positivity in glandular cells.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemical analysis of KDF1 in human Cerebral cortex using KDF1 Polyclonal Antibody (Product # PA5-55926) shows no positivity in neuronal cells as expected.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemical analysis of KDF1 in human Urinary bladder using KDF1 Polyclonal Antibody (Product # PA5-55926) shows moderate cytoplasmic positivity in urothelial cells.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 Expression of KDF1 in the tumor tissue of patients with clear cell renal cell carcinoma (ccRCC). Immunohistochemical staining was performed on the tumor tissue of 241 ccRCC patients while 39 non-tumor renal tissue samples were used as controls. The expression of KDF1 in the tumor tissue of 10 ccRCC patients was confirmed by Western blot while 10 non-tumor renal tissues were used as controls. (A) Representative pictures of immunohistochemistry. a: A representative picture from non-tumor renal tissue; b: A representative picture from ccRCC patients showing negative immunostaining for KDF1 (the KDF1 level was scored as 0); c: A representative picture from ccRCC patients showing weak immunostaining for KDF1 (the KDF1 level was scored as 1); d: A representative picture from ccRCC patients showing medium immunostaining for KDF1 (the KDF1 level was scored as 2); e: A representative picture from ccRCC patients showing strong immunostaining for KDF1 (the KDF1 level was scored as 3). (B) Results of Western blot analysis for KDF1 in the tumor tissue of 10 ccRCC patients and the matched non-tumor tissue. (C) Comparison of the KDF1 protein level between the tumor tissue of ccRCC patients and the non-tumor renal tissue according to the results of immunohistochemistry. (D) Quantitative analysis of the KDF1 protein level in the tumor tissue of 10 ccRCC patients compared with the non-tumor renal tissue according to the results of Western blot. a1-e1 is the local amplification of a-e

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 Effect of KDF1 overexpression on the proliferation, migration and invasion of ccRCC cells. Two ccRCC cell lines, 786-O and ACHN, were used in the experiments. The KDF1 overexpression ccRCC cells, 786-O-KDF1 and ACHN-KDF1, were constructed via stably infecting 786-O and ACHN cells with a recombinant KDF1 expression lentivirus. The overexpression of KDF1 in ccRCC cells were confirmed by quantitative RT-PCR and Western blot (A) and the influence of KDF1 overexpression in the proliferation (B) , migration (C) and invasion (D) of the ccRCC cells were evaluated by using CCK-8, wound healing and Matrigel invasion chamber methods. All the experiments were repeated at least three times. A, untransduced ACHN cells; A-VC, control virus transduced ACHN cells; A-K, KDF1 overexpression ACHN cells; O, untransduced 786-O cells; O-VC, control virus transduced 786-O cells; O-K, KDF1 overexpression 786-O cells. *p < 0.05; **p < 0.01. Scale bar, 100um.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 6 Knockdown of KDF1 reversed the effect of KDF1 overexpression on the ccRCC cell's proliferation, migration and invasion. A recombinant KDF1 shRNA expression lentivirus was used to knock down the expression of KDF1 in the KDF1 overexpression ccRCC cells. The knockdown of KDF1 expression was confirmed by quantitative RT-PCR and Western blot analysis (A) and the influence of KDF1 knockdown in the proliferation (B) , migration (C) and invasion (D) of the KDF1 overexpression ccRCC cells were evaluated by using CCK-8, wound healing and Matrigel invasion chamber methods. All the experiments were repeated at least three times. A, untransduced ACHN cells; A-K, KDF1 overexpression ACHN cells; A-K-sh, the KDF1 knockdown A-K; O, untransduced 786-O cells; O-K, KDF1 overexpression 786-O cells; O-K-sh, the KDF1 knockdown O-K; *p < 0.05; **p < 0.01. Scale bar, 100um.

PA5-55926

Antibody data